BIOMARCADORES PARA DIAGNÓSTICO DE ENFERMEDAD INFLAMATORIA INTESTINAL

Volver

Resultados 44 resultados LastUpdate Última actualización 23/09/2018 [16:01:00] pdf PDF




Solicitudes publicadas en los últimos 150 días / Applications published in the last 150 days



Página1 de 2 nextPage   Mostrar por página


POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS

NºPublicación: WO2018169818A1 20/09/2018

Solicitante:
WANG XIAODONG [US]

Resumen de: WO2018169818A1

The present invention provides a genus of polycyclic amines that are useful as opioid receptor modulators. The compounds of the invention are useful in both therapeutic and diagnostic methods, including for treating pain, neurological disorders, cardiac disorders, bowel disorders, drug and alcohol addiction, drug overdose, urinary disorders, respiratory disorders, sexual dysfunction, psoriasis, graft rejection or cancer.



traducir


 

POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS

NºPublicación: US2018258065A1 13/09/2018

Solicitante:
WANG XIAODONG [US]
ZHONG HUA [US]

Resumen de: US2018258065A1

The present invention provides a genus of polycyclic amines that are useful as opioid receptor modulators. The compounds of the invention are useful in both therapeutic and diagnostic methods, including for treating pain, neurological disorders, cardiac disorders, bowel disorders, drug and alcohol addiction, drug overdose, urinary disorders, respiratory disorders, sexual dysfunction, psoriasis, graft rejection or cancer.



traducir


 

COMPOSITIONS AND METHODS FOR DIAGNOSING COLON DISORDERS

NºPublicación: US2018251820A1 06/09/2018

Solicitante:
GEORGE MASON RES FOUNDATION INC [US]
RUSH UNIV [US]

Resumen de: US2018251820A1

The present invention relates to methods and compositions for diagnosing, monitoring, prognosticating, analyzing, etc., polymicrobial diseases. The present invention also relates to the microbial community present in the digestive tract and lumen in normal subjects, and subjects with digestive tract diseases, especially diseases of the colon, such as inflammatory bowel disease, including ulcerative colitis, Crohn's syndrome, and pouchitis. The present invention especially relates to compositions and methods for diagnosing and prognosticating the mentioned diseases and conditions, e.g., to determine the presence of the disease in a subject, to determine a therapeutic regimen, to determine the onset of active disease, to determine the predisposition to the disease, etc.



traducir


 

GENE SIGNATURES OF INFLAMMATORY DISORDERS THAT RELATE TO THE LIVER

NºPublicación: US2018251819A1 06/09/2018

Solicitante:
ENTEROME [FR]
NSTITUT NATIONAL DE LA RECH AGRONOMIQUE [FR]

Resumen de: US2018251819A1

This invention is related to the area of characterization of inflammation in relation with the gut microbiota, in metabolic and autoimmune disorders. In particular, it relates to the identification of gene signatures which can be used as a marker predictive of inflammation associated diseases, such as liver-related metabolic disorders, in particular to the evolution of benign steatosis towards its most severe forms (steatohepatitis and cirrhosis) or autoimmune disorders, in particular inflammatory bowel diseases (Crohn's and Ulcerative Colitis). These gene signatures can therefore be used as a means of diagnosis, prognosis, stratification for drug studies, for monitoring patient and for assigning an appropriate treatment.



traducir


 

HOST DNA AS A BIOMARKER OF CROHN'S DISEASE

NºPublicación: US2018251844A1 06/09/2018

Solicitante:
ENTEROME [FR]

Resumen de: US2018251844A1

The invention relates to methods of analysing a sample from a subject having or suspected of having Crohn's disease for the abundance of the subject's nucleic acid (e.g., DNA) in the sample. The invention also relates to methods for measuring abundance of nucleic acid (e.g., DNA) in stool from a human subject having or suspected of having Crohn's Disease (CD). In various embodiments, an in vitro method includes analysing the relative abundance of the host (human) DNA in said sample of stool or nucleic acid extracted or isolated from a stool sample from the host (human); determining the relative abundance of the host (human's) DNA in the sample; and associating the abundance of the host (human) DNA with the host (human) providing the stool sample, or the host (human) providing the stool sample from which the nucleic acid was extracted.



traducir


 

PREDICTION OF CLINICAL RESPONSE TO IL23-ANTAGONISTS USING IL23 PATHWAY BIOMARKERS

NºPublicación: US2018252728A1 06/09/2018

Solicitante:
AMGEN INC [US]
MEDIMMUNE LLC [US]

Resumen de: US2018252728A1

The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an ant-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.



traducir


 

Pathway specific assays for predicting irritable bowel syndrome diagnosis

NºPublicación: AU2018214104A1 30/08/2018

Solicitante:
NESTEC SA

Resumen de: AU2018214104A1

The present invention provides antibodies and methods for preparing antibodies to metabolites in the serotonin, tryptophan, kynurenine pathways. The prepared antibodies have low cross-reactivity to related metabolites, and are useful reagents for specific and 5 sensitive immunoassays The present invention also provides stable derivatives of various metabolites and short chain fatty acids. The derivative can be conjugated to a biomolecule such as a carrier protein and combined with an adjuvant to stimulate an immune response. The derivatives can also be conjugated to other biomolecules.



traducir


 

MEASUREMENT OF HYDROGEN SULFIDE DURING BREATH TESTING

NºPublicación: WO2018156937A1 30/08/2018

Solicitante:
CEDARS SINAI MEDICAL CENTER [US]

Resumen de: WO2018156937A1

Described herein are methods of detecting levels hydrogen sulfide (H2S) to diagnose H2S positive disease or conditions. Examples of H2S positive diseases and conditions include small intestinal bacterial overgrowth, diarrhea, fatigue, bowel urgency and abdominal pain. The H2S level can guide treatments for subjects who have high levels of H2S.



traducir


 

HUMANIZED ANTIBODIES SPECIFIC FOR HSP65-DERIVED PEPTIDE-6 METHODS AND USES THEREOF

NºPublicación: EP3366308A1 29/08/2018

Solicitante:
PROTAB LTD [IL]

Resumen de: EP3366308A1

The present invention relates to humanized antibodies that specifically bind a polypeptide comprising peptide-6 as denoted by SEQ ID NO. 15, that is an HSP65 derived peptide. More specifically, the invention relates to humanized anti-peptide-6 antibodies, compositions, methods and uses thereof for the treatment of immune-related disorders, specifically, inflammatory disorders such as arthritis, IBD, psoriasis, diabetes and MS. The invention further provides combined compositions and kit combining the humanized antibodies of the invention and at least one anti-inflammatory agent, as well as uses of the humanized antibodies in diagnostic kits and methods.



traducir


 

ULCERATIVE COLITIS (UC)-ASSOCIATED COLORECTAL NEOPLASIA MARKERS

NºPublicación: EP3366785A2 29/08/2018

Solicitante:
BAYLOR RES INSTITUTE [US]

Resumen de: EP3366785A2

Embodiments provide methods and compositions related to detecting neoplasia in ulcerative colitis patients by detection and analysis of the methylation state of miR-124, miR-137 and/or miR-34b/c in samples from UC patients.



traducir


 

TREATMENT WITH HIGHLY PURIFIED EICOSAPENTAENOIC ACID AS FREE FATTY ACID IMPROVES INFLAMMATION, AFFECTS COLONIC DIFFERENTIATION MARKERS AND MICROBIOTA IN PATIENTS WITH ULCERATIVE COLITIS

NºPublicación: WO2018150257A1 23/08/2018

Solicitante:
SLA PHARMA AG [CH]
RICCIARDIELLO LUIGI [IT]

Resumen de: WO2018150257A1

This present invention relates to the use of eicosapentaenoic acid (EPA) for the treatment of ulcerative colitis (UC), and more particularly, the use of highly purified eicosapentaenoic acid as free fatty acids (EPA-FFA) having a purity of at least 95% for reducing inflammation in a subject suffering from ulcerative colitis and wherein the levels of IL-10 and SOCS3 are increased and the microbiome of the intestinal mucosal tissue is favorably modulated.



traducir


 

VARIANTS OF TNFSF15 AND DCR3 ASSOCIATED WITH CROHN'S DISEASE

NºPublicación: US2018230543A1 16/08/2018

Solicitante:
CEDARS SINAI MEDICAL CENTER [US]

Resumen de: US2018230543A1

Described herein are methods and compositions related to the discovery of associations in TNFSF15 15 and DcR3 genetic loci across in Caucasian, Puerto Rican, and Korean Crohn's Disease, as demonstrated via trans-ethnic fine mapping. The present invention provides methods of quantifying risk and diagnosing susceptibility to Crohn's disease in a subject by determining the presence of one or more risk variants are at the TNFSF15 (or TL1A) and/or DcR3 genetic loci.



traducir


 

ANTIBODY TO CYTOLETHAL DISTENDING TOXIN OF CAMPYLOBACTER JEJUNI

NºPublicación: US2018231551A1 16/08/2018

Solicitante:
CEDARS SINAI MEDICAL CENTER [US]

Resumen de: US2018231551A1

Methods for preventing IBS, reducing the likelihood of developing IBS and/or treating IBS by administering COT inhibitors and/or COT neutralizers to a subject in need thereof are described. Methods of eliciting a specific immune response and methods of vaccinating a subject to prevent IBS or to reduce the likelihood of developing or having IBS are also provided. Methods of diagnosing IBS by detecting the presence or absence of COT or a COT marker in a subject are described.



traducir


 

HUMAN ANTIBODY MOLECULES FOR IL-13

NºPublicación: US2018230209A1 16/08/2018

Solicitante:
MEDIMMUNE LTD [GB]

Resumen de: US2018230209A1

Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralize IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.



traducir


 

METHODS FOR COLON HYPERPROLIFERATIVE DISORDER DETECTION, PROGNOSIS, AND DIAGNOSIS

NºPublicación: US2018224453A1 09/08/2018

Solicitante:
HUTCHINSON FRED CANCER RES [US]

Resumen de: US2018224453A1

The present disclosure provides methods of using certain biomarker expression profiles in the detection, diagnosis, prognosis, or development of treatment regimens for various cellular hyperproliferative disorders of the bowel. For example, pre-diagnostic methods comprise detecting whether the concentration of at least BAG4 in a test biological sample from a subject is elevated as compared to a control.



traducir


 

METHODS FOR DETECTING NOVEL AUTOANTIBODIES IN CROHN'S DISEASE

NºPublicación: US2018224448A1 09/08/2018

Solicitante:
UNIV ARIZONA STATE [US]
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RES [US]

Resumen de: US2018224448A1

Identification of autoantibodies associated with Crohn's disease useful in diagnosis and management using an innovative protein array technology, namely nucleic acid programmable protein arrays (NAPPA) and applications relating thereto. Overall, reactivity of IgG autoantibodies was stronger than that of IgA autoantibodies; however, IgA autoantibodies showed greater differential reactivity between cases and controls. Four IgA autoantibodies against SNRPB, PRPH, PTTG1 and SNAI1 were newly identified with sensitivities above 15% at 95% specificity, among which anti-SNRPB-IgA had the highest sensitivity of 24.0%. Autoantibodies associated with specific disease subtypes were also found.



traducir


 

PREDICTING A COMPLICATED COURSE FOR CHILDREN NEWLY DIAGNOSED WITH CROHN'S DISEASE

NºPublicación: WO2018140723A1 02/08/2018

Solicitante:
CROHNS AND COLITIS FOUND OF AMERICA [US]

Resumen de: WO2018140723A1

Provided herein is a method for identifying patients at risk for suffering complications from pediatric Crohn's disease, and methods of treating those patients to prevent the development of penetrating complications.



traducir


 

METHODS OF DIAGNOSIS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE

NºPublicación: US2018208988A1 26/07/2018

Solicitante:
CEDARS SINAI MEDICAL CENTER [US]

Resumen de: US2018208988A1

The present invention relates to methods of diagnosing and predicting susceptibility to Crohn's Diseaese and/or IBD, by determining the presence or absence of susceptibility to genetic variants, risk haplotypes and/or protective haplotypes. In an embodiment, the invention provides methods of diagnosing and/or predicting susceptibility to Crohn's Disease in an individual by determining the presence or absence of risk variants at the IL12RB1, IL12RB2, IL17A, IL17RA, IL17RD and/or IL23R locus.



traducir


 

METABOLIC BIOMARKERS OF CROHN'S DISEASE

NºPublicación: US2018203018A1 19/07/2018

Solicitante:
UNIV CALIFORNIA [US]

Resumen de: US2018203018A1

The invention provides for a method for identifying a biomarker in a fecal sample of a subject in need of such identification comprising: determining whether a fecal sample collected from a subject comprises a biomarker.



traducir


 

Antibodies for treatment and diagnosis of inflammatory bowel disease

NºPublicación: AU2016368529A1 19/07/2018

Solicitante:
PHILOGEN SPA

Resumen de: AU2016368529A1

The invention relates to the diagnosis and treatment of diseases,including inflammatory disorders, proliferative disorders and autoimmune diseases. The invention provides, and involves the use of, antibody molecules that bind: i) lysozyme, ii) neutrophil elastase, iii) tissue inhibitor of metalloproteinase-1 (TIMP-1), or iv) the D domain of Tenascin-C. The invention also relates to the use of antibody molecules that bind v) the IIICS isoform of fibronectin, vi) the Extra Domain-B (ED-B) of fibronectin, vii) matrix-metalloproteinase 3 (MMP3), or viii) the A1 domain of tenascin-C in the diagnosis and treatment of inflammatory disorders such as inflammatory bowel disease.



traducir


 

DIAGNOSIS OF INFLAMMATORY BOWEL SYNDROME BASED ON CYTOLETHAL DISTENDING TOXIN

NºPublicación: EP3349004A1 18/07/2018

Solicitante:
CEDARS SINAI MEDICAL CENTER [US]

Resumen de: EP3349004A1

The present invention describes methods for preventing IBS, reducing the likelihood of developing IBS and/or treating IBS by administering CDT inhibitors and/or CDT neutralizers to a subject in need thereof. The present invention also describes methods of eliciting a specific immune response and methods of vaccinating a subject to prevent IBS or to reduce the likelihood of developing or having IBS. The present invention further describes methods of diagnosing IBS by detecting the presence or absence of CDT or a CDT marker in a subject.



traducir


 

DIAGNOSIS AND TREATMENT OF IRRITABLE BOWEL SYNDROME AND INFLAMMATORY BOWEL DISEASE

NºPublicación: US2018196063A1 12/07/2018

Solicitante:
CEDARS SINAI MEDICAL CENTER [US]

Resumen de: US2018196063A1

The present invention describes methods, assays, and systems of diagnosing, selecting and treating irritable bowel syndrome (IBS) based on a subject's level of anti-vinculin and anti-CdtB antibodies. IBS can be distinguished from inflammatory bowel (IBD) disease using the methods, assays, and systems described herein.



traducir


 

PHARMACEUTICAL COMPOSITION COMPRISING INDIGO PULVERATA LEVIS EXTRACT OR FRACTION THEREOF AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE

NºPublicación: WO2018117659A1 28/06/2018

Solicitante:
SEOUL NAT UNIV HOSPITAL [KR]
DONG A ST CO LTD [KR]

Resumen de: WO2018117659A1

The present invention relates to a pharmaceutical composition comprising an Indigo Pulverata Levis extract or a fraction thereof as an effective ingredient for preventing or treating inflammatory bowel disease. Exhibiting the effect of reducing the activity and expression of inflammatory activation markers and alleviating the disease activity of inflammatory bowel disease, an Indigo Pulverata Levis extract or a fraction thereof according to the present invention is useful as an agent for preventing or treating inflammatory bowel disease.



traducir


 

METHOD OF TREATING CROHN'S DISEASE

NºPublicación: US2018171389A1 21/06/2018

Solicitante:
MURDOCH CHILDRENS RES INSTITUTE [AU]
ST VINCENTS HOSPITAL MELBOURNE [AU]

Resumen de: US2018171389A1

The invention relates to the treatment of inflammatory bowel disease characterised by chronic inflammation. In particular, the invention relates to methods of predicting, treating or preventing post-operative recurrence of Crohn's disease.



traducir


 

SINGLE VARIABLE DOMAIN ANTIBODIES AGAINST OX40L, CONSTRUCTS AND THERAPEUTIC USE

Nº publicación: US2018171019A1 21/06/2018

Solicitante:
ABLYNX NV [BE]
ABLYNX NV [BE]

Resumen de: US2018171019A1

The immunoglobulin single variable domains, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of inflammatory disease and/or disorder such as e.g. asthma, allergic asthma, chronic colitis, Crohn's disease, inflammatory bowel disease, and/or arthrosclerosis.


traducir



 

Página1 de 2 nextPage Mostrar por página

Volver